Skip to content
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Country/Region
  • No block ID is set

  • Clinic Portal
    • +0034963905310
  • Request Information
  • +34 96 390 53 10
  • Part of brands: |
InternationalInternational
  • Country/Region
  • Part of brands: |
  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
Genomics Precision Diagnostic > Neurology Precision Panel > Spinocerebellar Ataxia Precision Panel

Spinocerebellar Ataxia Precision Panel

Spinocerebellar Ataxia (SCA) refers to a heterogeneous group of progressive neurodegenerative diseases of genetic origin. Currently, more than 30 types have been described, most of which are autosomal dominant. Classification is done according to the clinical manifestations or genetic nosology. 
Overview
Indication
Clinical Utility
Genes & Diseases
Methodology
References

Overview

  • Spinocerebellar Ataxia (SCA) refers to a heterogeneous group of progressive neurodegenerative diseases of genetic origin. Currently, more than 30 types have been described, most of which are autosomal dominant. Classification is done according to the clinical manifestations or genetic nosology. The most common type is SCA3. Ataxia is defined as the absence of voluntary muscle coordination and loss of control of movement affecting gait stability, eye movement and speech. The clinical hallmark of SCA is loss of balance and coordination accompanied by slurred speech; onset is most often in adult life. The main disease mechanism of these SCAs include toxic RNA gain-of-function, mitochondrial dysfunction, channelopathies, autophagy and transcription dysregulation. The prognosis is dependent upon the individual and genetic properties, but most patients develop severe, irreversible disability, while retaining full mental capacity.

  • The Igenomix Spinocerebellar Ataxia Precision Panel can be used as a tool for an accurate diagnosis and differential diagnosis of loss of balance and coordination ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved, and their high or intermediate penetrance.

Indication

  • The Igenomix Spinocerebellar Ataxia Precision Panel is used for patients with a clinical suspicion or diagnosis presenting with or without the following symptoms: 
    • Broad based gait ataxia 
    • Tremor 
    • Limb ataxia 
    • Nystagmus 
    • Difficulty speaking 
    • Decreased coordination 
    • Dementia 

Clinical Utility

The clinical utility of this panel is: 

  • The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient.   
  • Early initiation of treatment involving a multidisciplinary team in the form of orthopaedic care, use of special devices to assist with fine movements as 
  • Risk assessment of asymptomatic family members according to the mode of inheritance via genetic counselling.  
  • Improvement of delineation of genotype-phenotype correlation given the variability of severity and course of disease.  

Genes & Diseases

Methodology

References

See scientific referrals

Sullivan, R., Yau, W. Y., O’Connor, E., & Houlden, H. (2019). Spinocerebellar ataxia: an update. Journal of neurology, 266(2), 533–544. https://doi.org/10.1007/s00415-018-9076-4 

Klockgether, T., Mariotti, C., & Paulson, H. L. (2019). Spinocerebellar ataxia. Nature reviews. Disease primers, 5(1), 24. https://doi.org/10.1038/s41572-019-0074-3 

Sun, Y. M., Lu, C., & Wu, Z. Y. (2016). Spinocerebellar ataxia: relationship between phenotype and genotype – a review. Clinical genetics, 90(4), 305–314. https://doi.org/10.1111/cge.12808 

Soong, B. W., & Morrison, P. J. (2018). Spinocerebellar ataxias. Handbook of clinical neurology, 155, 143–174. https://doi.org/10.1016/B978-0-444-64189-2.00010-X 

Manto, M. (2005). The wide spectrum of spinocerebellar ataxias (SCAs). The Cerebellum, 4(1), 2-6. doi: 10.1080/14734220510007914 

Spinocerebellar ataxia. (2019). Nature reviews. Disease primers, 5(1), 25. https://doi.org/10.1038/s41572-019-0081-4 

Coarelli, G., Brice, A., & Durr, A. (2018). Recent advances in understanding dominant spinocerebellar ataxias from clinical and genetic points of view. F1000Research, 7, F1000 Faculty Rev-1781. https://doi.org/10.12688/f1000research.15788.1 

descargar

Detail description

Download

Request Information

WE GUIDE YOU

Fertility
Inherited diseases prevention
Healthy pregnancy

To see the accreditation certificate, associated technical annex and list of accredited tests, click on this link.

OUR SERVICES

Genetic testing solutions
For patients
How to send a sample?
User manual

ABOUT US

About Igenomix
Contact
Quality
Complaints
Work with us
Terms and conditions

FOLLOW IGENOMIX

  + 96 390 53 10
  Write us
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
Country/Region

[2024] © Igenomix Privacy Page Quality policy Legal note Cookies policy

Request Information


  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
  • Country/Region
  • +34 96 390 53 10
  • Clinic Portal
  • Request Information